Home  |  Contact

Cellosaurus EM-2 (CVCL_1196)

[Text version]

Cell line name EM-2
Synonyms EM2
Accession CVCL_1196
Resource Identification Initiative To cite this cell line use: EM-2 (RRID:CVCL_1196)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Doubling time: ~35-40 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Bone marrow.
Sequence variations Homozygous for TP53 p.Arg248Gln (c.743G>A) (IARC_TP53 from Cosmic-CLP).
Disease Childhood chronic myelogenous leukemia, BCR-ABL1 positive (NCIt: C7320)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_2033 ! EM-3
Sex of cell Female
Age at sampling 5Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; PubMed=25877200

Penta D13,14
Penta E7,16

Run an STR similarity search on this cell line

Keating A., Martin P.J., Bernstein I.D., Papayannopoulou T., Raskind W., Singer J.W.
EM-2 and EM-3: two new Ph'+ myeloid cell lines.
(In) Normal and neoplastic hematopoiesis, UCLA symposia on molecular and cellular biology, New Series Vol. 9; Golde D.W., Marks P.M. (eds.); pp.513-520; Alan R. Liss; New York (1983)

PubMed=3856862; DOI=10.1073/pnas.82.6.1810
Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N.
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.
Proc. Natl. Acad. Sci. U.S.A. 82:1810-1814(1985)

PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9
Keating A.
Ph positive CML cell lines.
Baillieres Clin. Haematol. 1:1021-1029(1987)

PubMed=10637496; DOI=10.1038/sj.leu.2401604
Drexler H.G., Fombonne S., Matsuo Y., Hu Z.-B., Hamaguchi H., Uphoff C.C.
p53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization?
Leukemia 14:198-206(2000)

Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cell line collections DSMZ; ACC-135
Cell line databases/resources CLDB; cl1164
Cell_Model_Passport; SIDM01047
Cosmic-CLP; 906855
GDSC; 906855
Ontologies BTO; BTO:0005904
CLO; CLO_0002922
EFO; EFO_0002176
Biological sample resources BioSample; SAMN03472895
Chemistry resources ChEMBL-Cells; CHEMBL3308889
ChEMBL-Targets; CHEMBL2366281
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM887004
GEO; GSM888073
GEO; GSM1374474
GEO; GSM1669762
Other Wikidata; Q54832264
Polymorphism and mutation databases Cosmic; 787491
Cosmic; 906855
Cosmic; 994175
Cosmic; 1026572
Cosmic; 1078728
Cosmic; 1498416
IARC_TP53; 340
IARC_TP53; 21326